About Veyonda®

Our lead drug Veyonda® is a novel proprietary formulation of idronoxil, a first-in-class, dual-acting oncotoxic and immuno-oncology molecule.

The active ingredient in Veyonda® is the small molecule, idronoxil, under investigation for improving the effectiveness of immunotherapy, chemotherapy and radiation therapy treatment for a number of cancers.  

In cancer Veyonda® appears to have two actions, both directly killing cancer cells and working with the body’s immune system to destroy tumours, that is, as an immuno-oncology drug. 

LEARN MORE ABOUT VEYONDA®

Veyonda® is currently not approved in Australia or any other country